Compare COGT & APPF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COGT | APPF |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.9B |
| IPO Year | 2018 | 2015 |
| Metric | COGT | APPF |
|---|---|---|
| Price | $34.73 | $161.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 9 |
| Target Price | $36.21 | ★ $286.78 |
| AVG Volume (30 Days) | ★ 1.6M | 292.1K |
| Earning Date | 05-06-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.18 |
| Revenue | $7,871,000.00 | ★ $950,822,000.00 |
| Revenue This Year | N/A | $19.69 |
| Revenue Next Year | $1,733.58 | $16.70 |
| P/E Ratio | ★ N/A | $135.47 |
| Revenue Growth | N/A | ★ 19.72 |
| 52 Week Low | $5.10 | $142.73 |
| 52 Week High | $43.73 | $325.90 |
| Indicator | COGT | APPF |
|---|---|---|
| Relative Strength Index (RSI) | 50.38 | 50.31 |
| Support Level | $33.26 | $161.13 |
| Resistance Level | $37.69 | $165.95 |
| Average True Range (ATR) | 1.34 | 6.87 |
| MACD | 0.24 | 0.28 |
| Stochastic Oscillator | 72.74 | 72.29 |
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
AppFolio Inc provides cloud-based software solutions for the real estate industry. Its property management software offers property managers an end-to-end solution to their business needs. The group's products include cloud-based property management software (Appfolio Property Manager). Its solutions are AppFolio Property Manager Core, AppFolio Property Manager Plus, and AppFolio Property Manager Max. It also offers value-added services, such as screening, risk mitigation, and electronic payment services. Its markets are Single-Family, Multifamily, Student Housing, Affordable Housing, Community Associations, Commercial, and Investment Management. The business activity of the firm predominantly functions in the United States and it generates revenue in the form of subscription fees.